A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Alios BioPharma
- 19 Nov 2015 Results published in the New England Journal of Medicine
- 18 Nov 2015 According to an Alios BioPharma media release, results will be published in the New England Journal of Medicine (NEJM).
- 18 Nov 2015 Results published in an Alios BioPharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History